Applied Therapeutics Stock Today
APLT Stock | USD 10.21 0.62 6.47% |
Performance9 of 100
| Odds Of DistressLess than 39
|
Applied Therapeutics is selling for under 10.21 as of the 27th of November 2024; that is 6.47 percent increase since the beginning of the trading day. The stock's last reported lowest price was 9.45. Applied Therapeutics has about a 39 percent probability of financial distress in the next few years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for Applied Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 3rd of December 2023 and ending today, the 27th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 14th of May 2019 | Category Healthcare | Classification Health Care |
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York. The company has 116.36 M outstanding shares of which 12.14 M shares are presently shorted by private and institutional investors with about 7.7 trading days to cover. More on Applied Therapeutics
Moving together with Applied Stock
0.79 | BMY | Bristol Myers Squibb Sell-off Trend | PairCorr |
Moving against Applied Stock
Applied Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
Average Analyst Recommendation | |||||
Debt LevelsApplied Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Applied Therapeutics' financial leverage. It provides some insight into what part of Applied Therapeutics' total assets is financed by creditors.
|
Applied Therapeutics (APLT) is traded on NASDAQ Exchange in USA. It is located in 545 Fifth Avenue, New York, NY, United States, 10017 and employs 37 people. Applied Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.19 B. Applied Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 116.36 M outstanding shares of which 12.14 M shares are presently shorted by private and institutional investors with about 7.7 trading days to cover.
Applied Therapeutics currently holds about 67.72 M in cash with (55.17 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.41.
Check Applied Therapeutics Probability Of Bankruptcy
Ownership AllocationThe majority of Applied Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Applied Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Applied Therapeutics. Please pay attention to any change in the institutional holdings of Applied Therapeutics as this could imply that something significant has changed or is about to change at the company.
Check Applied Ownership Details
Applied Stock Institutional Holders
Instituion | Recorded On | Shares | |
Adage Capital Partners Gp Llc | 2024-06-30 | 2.8 M | |
Tang Capital Management Llc | 2024-09-30 | 2.7 M | |
Deutsche Bank Ag | 2024-06-30 | 2.3 M | |
Geode Capital Management, Llc | 2024-09-30 | 2.1 M | |
State Street Corp | 2024-06-30 | 1.7 M | |
Rock Springs Capital Management Lp | 2024-06-30 | 1.6 M | |
Stempoint Capital Lp | 2024-09-30 | 1.6 M | |
Opaleye Management Inc | 2024-09-30 | 1.3 M | |
Soleus Capital Management, L.p. | 2024-06-30 | 1.3 M | |
Vr Adviser, Llc | 2024-09-30 | 9.8 M | |
Perceptive Advisors Llc | 2024-09-30 | 8 M |
Applied Therapeutics Historical Income Statement
Applied Stock Against Markets
Applied Therapeutics Corporate Management
Riccardo MD | Chief Officer | Profile | |
Chids Mahadevan | Sr Officer | Profile | |
Steven Ortega | Chief Officer | Profile | |
Catherine Thorpe | Chief Officer | Profile | |
Adam Hansard | Chief Officer | Profile |
Already Invested in Applied Therapeutics?
The danger of trading Applied Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Applied Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Applied Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Applied Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Applied Stock Analysis
When running Applied Therapeutics' price analysis, check to measure Applied Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Applied Therapeutics is operating at the current time. Most of Applied Therapeutics' value examination focuses on studying past and present price action to predict the probability of Applied Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Applied Therapeutics' price. Additionally, you may evaluate how the addition of Applied Therapeutics to your portfolios can decrease your overall portfolio volatility.